Bhatia Sangeeta N. 4

What Happened

• Sangeeta N. Bhatia, a director of Vertex Pharmaceuticals (VRTX), sold 318 shares in an open-market transaction on 2026-05-04 at $423.73 per share for proceeds of $134,746.
• She was also granted 943 restricted stock units (RSUs) on 2026-05-01 (reported at $0.00 in the filing); these RSUs vest, with limited exceptions, on the first anniversary of the grant (see footnote F1).
• The sale was made pursuant to a company-approved Rule 10b5-1 trading plan entered on 05/27/2025 (footnote F2), which indicates the sale was pre-planned rather than a spontaneous trade.

Key Details

• Transaction dates and prices: 2026-05-01 grant (943 RSUs, $0.00 reported); 2026-05-04 sale of 318 shares at $423.73 each (total ~$134,746).
• Shares owned after transaction: not disclosed in the provided filing.
• Footnotes: F1 = RSU award vests on first anniversary; F2 = sale executed under a 10b5-1 trading plan entered 05/27/2025.
• Filing: Report filed 2026-05-05 covering the 5/1 and 5/4 transactions; no late-filing flag noted in this filing excerpt.

Context

• RSU grants are awards that convert to shares only after vesting; the 943 RSUs do not represent immediately tradable shares.
• Sales made under a 10b5-1 plan are typically pre-scheduled and are often considered routine rather than a direct signal of insider sentiment.
• For retail investors, purchases are usually more informative of confidence than routine sales; this filing shows a planned sale plus a typical director RSU grant.